Cargando…

Mesalazine/tofacitinib/vedolizumab: COVID-19 infection: 3 case reports

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520069/ http://dx.doi.org/10.1007/s40278-021-03812-9

Ejemplares similares

Adalimumab/ustekinumab/vedolizumab: COVID-19 infection: 7 case reports
Publicado: (2022)

Adalimumab/vedolizumab: Gastroparesis and COVID infection: case report
Publicado: (2021)

Azathioprine/infliximab/mesalazine: Coronavirus disease-19: case report
Publicado: (2020)

Mesalazine-induced myocarditis: a case report
por: Radhakrishnan, Shiva T., et al.
Publicado: (2018)

Mesalazine-induced myopericarditis: a case report
por: Shergill, Simran
Publicado: (2020)

Adalimumab/mercaptopurine/mesalazine: Epstein-Barr virus and cytomegalovirus infections: case report
Publicado: (2022)

Myocarditis Related to the Use of Mesalazine
por: Kyriakou, Michaela, et al.
Publicado: (2023)

Methotrexate/tofacitinib/tozinameran interaction: COVID-19 pneumonia: case report
Publicado: (2022)

Mesalazine/prednisolone: Perimyocarditis, rebound effect and lack of efficacy: 2 case reports
Publicado: (2021)

Hypersensitivity to mesalazine in a patient with inflammatory bowel disease: a case report
por: Cronin, Kevin C, et al.
Publicado: (2009)

Adalimumab/vedolizumab: SARS-CoV-2 infection: 2 case reports
Publicado: (2021)

Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease
por: Restellini, Sophie, et al.
Publicado: (2021)

Favorable Outcomes Combining Vedolizumab With Other Biologics or Tofacitinib for Treatment of Inflammatory Bowel Disease
por: Llano, Ernesto M, et al.
Publicado: (2021)

Mesalazine-induced eosinophilic pneumonia with bone marrow infiltration: a case report and literature review
por: Zhang, Yunjian, et al.
Publicado: (2016)

Tofacitinib for Prurigo Nodularis: A Case Report
por: Peng, Changlan, et al.
Publicado: (2022)

Ulcerative colitis successfully treated with vedolizumab in the presence of comorbid opportunistic infections: a case report
por: Oki, Yusuke, et al.
Publicado: (2023)

Mesalazine-induced myopericarditis: a case series
por: Andrei, Valentina, et al.
Publicado: (2023)

A Case of Evan's Syndrome Induced by Vedolizumab
por: Jen, Henry, et al.
Publicado: (2019)

Acute eosinophilic pneumonia related to a mesalazine suppository
por: Kim, Jung Hyun, et al.
Publicado: (2013)

Mesalazine-induced myopericarditis in a patient with ulcerative colitis
por: Asadi, Jalal, et al.
Publicado: (2017)

Severe Lupus Myocarditis Preceded by Mesalazine-induced Lupus
por: Yamashita, Mai, et al.
Publicado: (2022)

Tofacitinib as an Adjunct Immunomodulator for Treatment of a Patient with Severe COVID-19: A Case Report
por: Shrestha, Gentle Sunder, et al.
Publicado: (2021)

Dexamethasone/prednisone/tofacitinib: COVID-19, thromboembolic episodes and off-label use: case report
Publicado: (2021)

Case report of patient with a Cronkhite-Canada syndrome: sustained remission after treatment with corticosteroids and mesalazine
por: Schulte, Sigrid, et al.
Publicado: (2019)

Vedolizumab-Associated Hypereosinophilia and Hepatoxicity
por: De Marco, Davide, et al.
Publicado: (2022)

Tofacitinib: Increased D-Dimer level: case report
Publicado: (2021)

Comparing Patient-Reported Outcomes Among Anti-TNF Experienced Patients With Ulcerative Colitis Initiating Vedolizumab Versus Tofacitinib
por: Kappelman, Michael D, et al.
Publicado: (2023)

Su1485: COVID-19 VACCINE-INDUCED ANTIBODY RESPONSES ARE IMPAIRED IN IBD PATIENTS TREATED WITH INFLIXIMAB, USTEKINUMAB OR TOFACITINIB, BUT NOT THIOPURINES OR VEDOLIZUMAB
por: Alexander, James L., et al.
Publicado: (2022)

Infliximab/vedolizumab: Drug-induced lupus, pneumonitis and lack of efficacy: case report
Publicado: (2021)

Vedolizumab in Crohn’s disease with rectal fistulas and presacral abscess: A case report
por: Yeh, Heng, et al.
Publicado: (2021)

Vedolizumab in the treatment of immune checkpoint inhibitor-induced colitis: Two case reports
por: Zhang, Zhe, et al.
Publicado: (2022)

Recurrent Mesalazine-Induced Myopericarditis in a Patient with Ulcerative Colitis
por: Park, Eun Hye, et al.
Publicado: (2012)

Tofacitinib in recalcitrant scleritis: First case report from India
por: Pyare, Richa, et al.
Publicado: (2020)

Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland
por: Petryszyn, Pawel, et al.
Publicado: (2020)

Glucocorticoids combined with tofacitinib in the treatment of Castleman's disease: A case report
por: Liu, Xiao-Rui, et al.
Publicado: (2022)

Drug-induced liver injury due to tofacitinib: a case report
por: Mardani, Masoud, et al.
Publicado: (2023)

Relieving severe itching caused by scabies with tofacitinib: A case report
por: Yu, Zhenze, et al.
Publicado: (2023)

Vedolizumab-associated diffuse interstitial lung disease in patients with ulcerative colitis: A case report
por: Zhang, Jie, et al.
Publicado: (2022)

Nonasthmatic eosinophilic bronchitis in an ulcerative colitis patient – a putative adverse reaction to mesalazine: A case report and review of literature
por: Cernomaz, Andrei Tudor, et al.
Publicado: (2020)

Vedolizumab Therapy in Refractory Enteropathy Associated With CVID
por: Johnson, Dane, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4od96assu64romm247l8gmr40t